Search

Displaying results 3681 - 3690 of 5419 in total
  1. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vita...

  2. Drug

    PRO-542

    go.drugbank.com/drugs/DB05793
    Investigational

    PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutraliz...

  3. Drug

    Penamecillin

    go.drugbank.com/drugs/DB13739
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Cefsulodin

    go.drugbank.com/drugs/DB13499
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Cefazedone

    go.drugbank.com/drugs/DB13778
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Aspoxicillin

    go.drugbank.com/drugs/DB13816
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the Un...

  8. Drug

    Talsupram

    go.drugbank.com/drugs/DB09191
    Experimental

    It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to [citalopram].

  9. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    [A193506] SEP-363856 was developed by Sunovion pharmaceuticals. … Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5

  10. Drug

    ChulaCov19 mRNA vaccine

    go.drugbank.com/drugs/DB16445
    Experimental

    The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678].